- Case report
- Open Access
- Open Peer Review
POLG1 mutations and stroke like episodes: a distinct clinical entity rather than an atypical MELAS syndrome
© Cheldi et al.; licensee BioMed Central Ltd. 2013
- Received: 3 February 2012
- Accepted: 3 January 2013
- Published: 15 January 2013
POLG1 mutations have been associated with MELAS-like phenotypes. However given several clinical differences it is unknown whether POLG1 mutations are possible causes of MELAS or give raise to a distinct clinical and genetic entity, named POLG1-associated encephalopathy.
We describe a 74 years old man carrying POLG1 mutations presenting with strokes, myopathy and ragged red fibers with some atypical aspects for MELAS such as late onset, lack of cerebral calcification and presence of frontal and occipital MRI lesions better consistent with the POLG associated-encephalopathy spectrum.
The lack of available data hampers a definite diagnosis in our patient as well as makes it difficult to compare MELAS, which is a clearly defined clinical syndrome, with POLG1-associated encephalopathy, which is so far a purely molecularly defined syndrome with a quite heterogeneous clinical picture. However, the present report contributes to expand the phenotypic spectrum of POLG1 mutations underlining the importance of searching POLG1 mutations in patients with mitochondrial signs and MELAS like phenotypes but negative for common mtDNA mutations.
- Red-ragged fibers
Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome is a phenotypically and genetically heterogeneous mitochondrial disorder. Stroke-like episodes, which are usually transient and not-disabling, represent the clinical hallmarks. Additional features include seizures, cognitive decline, psychosis, lactic acidosis, migraine, visual impairment, hearing loss, short stature, diabetes and myopathy. MRI shows hyperintensities on T2-weighted and DWI sequences mostly over the temporal, parietal and occipital regions, not confined to a vascular territory. Muscle biopsy typically shows ragged-red and COX-negative fibers, SDH hyperreactivity and, at ultrastructural level, abnormally shaped mitochondria with paracristalline inclusions. MELAS results in 80% of cases from a point mutation, m.3243A>G in the mitochondrial tRNALeu(UUR) gene (MTTL1) [1, 2]. Other mitochondrial DNA (mtDNA) mutations in MTTL1 gene and other transfer RNA genes (MTTF, MTTV, MTTQ) as well as mutations in other subunits of complex 1 such as MTND1, MTND5 and MTND6 have been also identified as cause of MELAS [3–6]. Indeed, mutations in nuclear genes leading to secondary mtDNA changes (depletions and multiple deletions), have been described as emerging causes of MELAS . Recently, Deschauer et al. described a patient showing stroke-like episodes and a right occipital lesion, headache, seizures, elevated CSF lactate, ragged–red fibers and carrying heterozygous mutations in mtDNA polymerase gene (POLG1) arguing that MELAS could be included in POLG1 spectrum phenotype . POLG1 mutations were described, so far, in families with autosomal dominant and recessive chronic progressive external ophthalmoplegia (PEO), Alpers syndrome, parkinsonism, optic neuritis and late onset ataxia [8, 9]. We previously reported a cohort of 67 patients affected by myopathy with or without PEO, in which 19.4% of patients carried POLG1 mutations . Herein, we report the 2-year neurological follow up of one of these patients disclosing over time a clinical phenotype highly consistent with MELAS.
Skeletal muscle and nerve histopathology
In 2004 the patient underwent a left biceps skeletal muscle biopsy. Cryostatic cross sections were processed according to standard histological and histochemical techniques including Haematoxylin & Eosin (H&E), Gomori Trichrome (GT), Cytochrome c Oxidase (COX), Succinate Dehydrogenase (SDH) and double reaction for COX and SDH . Electron microscopy studies were performed as described .
Histological examination of muscle specimen showed slight fiber size variability, some nuclear centralizations and several fiber splittings along with a consistent number (n=10) of ragged red fibers (RRF). Necrosis was observed in a few fibers. Histochemically, several fibers were Cytochrome c Oxidase (COX)-negative, many of these fibers were also intensely SDH-positive (Figure 1).
DNA sample and muscle biopsy were collected after obtaining patient informed consent according to the local ethics and privacy and human subjects’ protection regulations and were taken as part of standard patient care.
The human mitochondrial genome is replicated by the DNA polymerase γ, pol γ, which is encoded by POLG1, which is a 23 exons nuclear gene located on chromosome 15q25. Heterozygous and homozygous POLG1 mutations have been typically associated with heterogeneous and severe clinical phenotypes of PEO, both in autosomal dominant or recessive form. They can also result in adult onset cerebellar ataxia with mtDNA multiple deletions and Alpers syndrome, an autosomal recessive hepatocerebral disease characterized by severe developmental delay, intractable seizures, liver failure and death in childhood. Moreover, throughout the years a wide spectrum of clinical findings including parkinsonism, neuropathy, optic neuritis, psychiatric disorders has been described in POLG1 mutations carriers [12, 14–19]. Deschauer et al. 2007 described a patient presenting with occipital seizures and residual homonymous hemianopsia, headache and ataxia and carrying two heterozygous POLG1 mutations . The presence of occipital symptoms and lesions, interpreted as stroke-like episodes, together with elevated CSF lactate and ragged red fibers, posed the suspicion of MELAS, raising the question whether POLG1 mutations could be associated with a MELAS like phenotype [7, 20]. However, given several clinical differences between POLG1 patient characteristics and MELAS, it has been supposed that, despite some overlapping symptoms, POLG1 represent a distinct clinical and genetic entity. POLG-associated encephalopathy has been postulated to give rise to a distinct phenotype, including variable age at onset, either recessive or dominant inheritance pattern and peculiar neuroimaging findings characterized by predominant posterior ischemic lesions and lack of cerebral calcification .
Our case had some atypical aspects for MELAS such as late onset, lack of cerebral calcification and presence of frontal and occipital MRI lesions better consistent with the POLG associated-encephalopathy spectrum. However, it is difficult to assess with certainty whether our patient could be classified as MELAS-like or POLG-associated encephalopathy. Moreover, although the patient did not present any vascular risk factor, given the elderly age a co-incidence between a POLG myopathy and a cerebrovascular disease can not be excluded at all.
However, it is difficult to compare MELAS, which is a clearly defined clinical syndrome, with POLG1-associated encephalopathy, which is so far a purely molecularly defined syndrome with a quite heterogeneous clinical picture. In addition, although 140 POLG mutations have been described in patients with symptoms that suggest mitochondrial disease, most of mutations are reported in heterozygous in whom each POLG allele can be one or more different mutations and only few of these has been replicated in not related families. This makes difficult a clear definition of phenotype and in providing evidence of the disease causing nature of these mutations .
Our patient harboured the haplotype p.[T251I P587L] in combination with D1186H located in polymerase domain. The haplotype T251I and P587L has been already described but it is currently not possible to know whether T251I or P587L is the primary pathogenic allele or whether both mutations are necessary to cause disease. Nevertheless both variants have also been reported in trans one each other in affected subjects. Notably both P587 and D1186 residues are located in the DNA binding channel of POLG enzyme. Thus, the substitutions found in our patient could be consistent with a reduced DNA binding capacity.
However, given the lack of available data, the implementation of existing databases (http://tools.niehs.nih.gov/polg/) including single unpublished observations from clinicians, is necessary to determine allelic frequencies of the myriad of POLG1 mutations [22, 23]. Ongoing studies on biochemical measurements of polymerase activity and in vivo measurement of mitochondrial dysfunction will provide further issue on their pathogenic role.
The present report contributes to expand the phenotypic spectrum of POLG1 mutations underlining the importance of searching POLG1 mutations in patients with mitochondrial signs and MELAS like phenotypes but negative for common mtDNA mutations.
Written informed consent was obtained from the patient for the publication of this case report and any accompanying images.
We wish to thank ‘LOMBARDIA GENS’ network and project for their support. The existent network and the research grants of Regione Lombardia is gratefully acknowledged. The financial support of Associazione Amici del Centro Dino Ferrari, University of Milan, the Telethon project GTB07001, the Eurobiobank project QLTR-2001-02769 and R.F. 02.187 Criobanca Automatizzata di Materiale Biologico are gratefully acknowledged. Written consent was obtained from the patient for publication.
- Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP: Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol. 1984, 16: 481-488.View ArticlePubMedGoogle Scholar
- Goto Y, Nonaka I, Horai S: A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. 1990, 348: 651-653.View ArticlePubMedGoogle Scholar
- Di Mauro S, Schon EA: Mitochondrial respiratory-chain diseases. N Engl J Med. 2003, 348: 2656-68.View ArticleGoogle Scholar
- Liolitsa D, Rahman S, Benton S, Carr LJ, Hanna MG: Is the mitochondrial complex I ND5 gene a hot-spot for MELAS causing mutations?. Ann Neurol. 2003, 53: 128-132.View ArticlePubMedGoogle Scholar
- Ravn K, Wibrand F, Hansen FJ, Horn N, Rosenberg T, Schwartz M: An mtDNA mutation, 14453G–>A, in the NADH dehydrogenase subunit 6 associated with severe MELAS syndrome. Eur J Hum Genet. 2001, 9: 805-809.View ArticlePubMedGoogle Scholar
- Kirby DM, McFarland R, Ohtake A, Dunning C, Ryan MT, Wilson C, Ketteridge D, Turnbull DM, Thorburn DR, Taylor RW: Mutations of the mitochondrial ND1 gene as a cause of MELAS. J Med Genet. 2004, 41: 784-789.View ArticlePubMedPubMed CentralGoogle Scholar
- Deschauer M, Tennant S, Rokicka A, He L, Kraya T, Turnbull DM, Zierz S, Taylor RW: MELAS associated with mutations in the POLG1 gene. Neurology. 2007, 68: 1741-1742.View ArticlePubMedGoogle Scholar
- Horvath R, Hudson G, Ferrari G, Fütterer N, Ahola S, Lamantea E, Prokisch H, Lochmüller H, McFarland R, Ramesh V, Klopstock T, Freisinger P, Salvi F, Mayr JA, Santer R, Tesarova M, Zeman J, Udd B, Taylor RW, Turnbull D, Hanna M, Fialho D, Suomalainen A, Zeviani M, Chinnery PF: Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. Brain. 2006, 129: 1674-1684.View ArticlePubMedGoogle Scholar
- Echaniz-Laguna A, Chassagne M, de Sèze J, Mohr M, Clerc-Renaud P, Tranchant C, Mousson de Camaret B: POLG1 variations presenting as multiple sclerosis. Arch Neurol. 2010, 67: 1140-1143.View ArticlePubMedGoogle Scholar
- Virgilio R, Ronchi D, Hadjigeorgiou GM, Bordoni A, Saladino F, Moggio M, Adobbati L, Kafetsouli D, Tsironi E, Previtali S, Papadimitriou A, Bresolin N, Comi GP: Novel Twinkle (PEO1) gene mutations in mendelian progressive external ophthalmoplegia. J Neurol. 2008, 255: 1384-1391.View ArticlePubMedGoogle Scholar
- Zeviani M, Gellera C, Pannacci M, Uziel G, Prelle A, Servidei S, DiDonato S: Tissue distribution and transmission of mitochondrial DNA deletions in mitochondrial myopathies. Ann Neurol. 1990, 28: 94-97.View ArticlePubMedGoogle Scholar
- Davidzon G, Mancuso M, Ferraris S, Quinzii C, Hirano M, Peters HL, Kirby D, Thorburn DR, DiMauro S: POLG mutations and Alpers syndrome. Ann Neurol. 2005, 57: 921-923.View ArticlePubMedGoogle Scholar
- Sciacco M, Prelle A, Comi GP, Napoli L, Battistel A, Bresolin N, Tancredi L, Lamperti C, Bordoni A, Fagiolari G, Ciscato P, Chiveri L, Perini MP, Fortunato F, Adobbati L, Messina S, Toscano A, Martinelli-Boneschi F, Papadimitriou A, Scarlato G, Moggio M: Retrospective study of a large population of patients affected with mitochondrial disorders: clinical, morphological and molecular genetic evaluation. J Neurol. 2001, 248: 778-788.View ArticlePubMedGoogle Scholar
- Van Goethem G, Dermaut B, Löfgren A, Martin JJ, Van Broeckhoven C: Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet. 2001, 28: 211-212.View ArticlePubMedGoogle Scholar
- Hakonen AH, Heiskanen S, Juvonen V, Lappalainen I, Luoma PT, Rantamaki M, Goethem GV, Lofgren A, Hackman P, Paetau A, Kaakkola S, Majamaa K, Varilo T, Udd B, Kaariainen H, Bindoff LA, Suomalainen A: Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. Am J Hum Genet. 2005, 77: 430-441.View ArticlePubMedPubMed CentralGoogle Scholar
- Del Bo R, Bordoni A, Sciacco M, Di Fonzo A, Galbiati S, Crimi M, Bresolin N, Comi GP: Remarkable infidelity of polymerase gammaA associated with mutations in POLG1 exonuclease domain. Neurology. 2003, 61: 903-908.View ArticlePubMedGoogle Scholar
- Lamantea E, Tiranti V, Bordoni A, Toscano A, Bono F, Servidei S, Papadimitriou A, Spelbrink H, Silvestri L, Casari G, Comi GP, Zeviani M: Mutations of mitochondrial DNA polymerase gammaA are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia. Ann Neurol. 2002, 52: 211-219.View ArticlePubMedGoogle Scholar
- González-Vioque E, Blázquez A, Fernández-Moreira D, Bornstein B, Bautista J, Arpa J, Navarro C, Campos Y, Fernández-Moreno MA, Garesse R, Arenas J, Martín MA: Association of novel POLG mutations and multiple mitochondrial DNA deletions with variable clinical phenotypes in a Spanish population. Arch Neurol. 2006, 63: 107-111.View ArticlePubMedGoogle Scholar
- Tzoulis C, Engelsen BA, Telstad W, Aasly J, Zeviani M, Winterthun S, Ferrari G, Aarseth JH, Bindoff LA: The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain. 2006, 129: 1685-1692.View ArticlePubMedGoogle Scholar
- Tzoulis C, Bindoff LA: Melas associated with mutations in the POLG1 gene. Neurology. 2008, 70: 1054-View ArticlePubMedGoogle Scholar
- Tzoulis C, Neckelmann G, Mørk SJ, Engelsen BE, Viscomi C, Moen G, Ersland L, Zeviani M, Bindoff LA: Localized cerebral energy failure in DNA polymerase gamma-associated encephalopathy syndromes. Brain. 2010, 133: 1428-1437.View ArticlePubMedGoogle Scholar
- Stumpf JD, Copeland WC: Mitochondrial DNA replication and disease: insights from DNA polymerase γ mutations. Cell Mol Life Sci. 2011, 68: 219-233.View ArticlePubMedGoogle Scholar
- Hirano M, Ricci E, Koenigsberger MR, Defendini R, Pavlakis SG, DeVivo DC, DiMauro S, Rowland LP: Melas: an original case and clinical criteria for diagnosis. Neuromuscul Disord. 1992, 2: 125-135.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/13/8/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.